Charles River Laboratories Intl. Inc vs Duke Energy Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Duke Energy Corp trades at $116.65 (market cap $91.10B). The key difference: Duke Energy Corp is far larger — about 6.4× Charles River Laboratories Intl. Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Duke Energy Corp for 74 Days on average.
| CRL | DUK | |
|---|---|---|
Market Cap | $14.23B | $91.10B |
Volume | 1,176,885 | 4,199,050 |
Sector | Health | Utilities |
52-Week High | $310.77 | $133.46 |
52-Week Low | $149.93 | $113.23 |
Typical Hold Time | 33 Days | 74 Days |
Enterprise Value | $17.06B | $183.61B |
Dividend Yield | — | 3.71% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Duke Energy (DUK) trades at $116.84, up 1.16% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 17.6, net income margin of 15.78%, and robust cash flow from operations of $12.33B in 2025. Recent news highlights dividend declarations and data center growth opportunities, while analyst consensus is mixed with a $134.44 price target.
DUK offers a stable investment with reliable dividends and growth from data center demand, but faces risks from rising Treasury yields, high debt levels, and regulatory pressures. The stock's valuation is reasonable, and institutional interest remains positive, though technical indicators suggest near-term resistance at $118.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →